Arcutis Biotherapeutics(NASDAQ) ARQT

Arcutis Biotherapeutics, Inc. creates creams and foams that help people with chronic skin conditions like psoriasis and eczema. These treatments provide relief from itching and rashes without using steroids. The company focuses on making medicines that are safe for long-term use by adults and children.

Creams, Foams, and Clinical Trials

• ZORYVE Cream 0.3%: Once-daily topical treatment for plaque psoriasis in patients age 2 and older.
• ZORYVE Foam 0.3%: Steroid-free medication used for seborrheic dermatitis and psoriasis on the scalp or body.
• ZORYVE Cream 0.15%: Treatment for mild to moderate atopic dermatitis in adults and children at least 6 years old.
• ZORYVE Cream 0.05%: Lower-strength medication for atopic dermatitis in children age 2 to 5.
• ARQ-234: Injectable biologic candidate currently in clinical trials for moderate to severe atopic dermatitis.

Expanding the Portfolio

• Launched ZORYVE cream 0.3% for plaque psoriasis in August 2022 after receiving initial regulatory approval.
• Acquired Ducentis BioTherapeutics in September 2022 to add an injectable biologic treatment to its product pipeline.
• Established licensing deals with Huadong Medicine in August 2023 and Sato Pharmaceutical in February 2024 for international markets.
• Built an internal sales team in Jan. 2026 after ending a promotion agreement with Kowa Pharmaceuticals America.

Patented Science and Broad Protection

Arcutis develops steroid-free treatments using phosphodiesterase-4 inhibitors, which are enzymes that help control inflammation in the body. The company secures its market position through a patent portfolio that protects its specific formulations until 2037 and 2042.

The Midyear Financial Summary

• Total product revenue was $235.3 million for the six months ended June 30, 2026, up 62% year over year.
• Revenue from ZORYVE foam reached $117.0 million for the six months ended June 30, 2026, up 68% year over year.
• Net income for the six months ended June 30, 2026, was $3.7 million, compared to a net loss of $40.9 million in the prior year.
• Market capitalization was $3.4 billion in the second quarter of 2026, up 92.2% year over year.
• The company reported $238.9 million in cash and marketable securities as of June 30, 2026.

Bottom Line

Arcutis has transitioned from a research firm to a commercial company with multiple skin treatments on the market. It is expanding product labels and building its own sales force to establish a long-term market presence.